The pharmacodynamics of antiplatelet compounds in thrombosis treatment

Thanasekaran Jayakumar, Chih Hao Yang, Pitchairaj Geraldine, Ting Lin Yen, Joen Rong Sheu

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

ABSTRACT: Introduction: As it is importance to understand the involvement of platelets in the initiation and propagation of thrombosis, antiplatelet drugs have come to the forefront of atherothrombotic disease treatment. Dual antiplatelet therapy of aspirin plus clopidogrel has its benefits, but it also has its limitations with regard to its pharmacologic properties and adverse effects. For these reasons, within the last decade or so, the investigation of novel antiplatelet agents has prospered. Areas covered: In this review, we discuss the unique pharmacodynamic properties of several antiplatelet drugs with their possible potential molecular of mechanisms on inhibiting platelet aggregation. Expert opinion: Considering multiple synergetic pathways of platelet activation and their close interplay with coagulation, the current treatment strategies are not only based on platelet inhibition, they also rely on the attenuation of procoagulant activity, inhibition of thrombin generation, and enhancement of clot dissolution. Current guidelines recommend various antiplatelet agents in addition to aspirin for patients with acute coronary syndromes. The advantages of these agents, as repute mortality, may be associated with off-target effects of the drug. Hence, further studies are required to facilitate the physician’s choice of the most appropriate antiplatelet agents for each patient for thrombosis treatment.

Original languageEnglish
Pages (from-to)615-632
Number of pages18
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 2 2016

Fingerprint

Pharmacodynamics
Platelet Aggregation Inhibitors
Platelets
Thrombosis
clopidogrel
Aspirin
Blood Platelets
Therapeutics
Platelet Activation
Expert Testimony
Acute Coronary Syndrome
Coagulation
Platelet Aggregation
Thrombin
Dissolution
Agglomeration
Chemical activation
Guidelines
Physicians
Mortality

Keywords

  • Antiplatelets
  • antithrombotic
  • multi-targets
  • pharmacodynamics

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

The pharmacodynamics of antiplatelet compounds in thrombosis treatment. / Jayakumar, Thanasekaran; Yang, Chih Hao; Geraldine, Pitchairaj; Yen, Ting Lin; Sheu, Joen Rong.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 12, No. 6, 02.06.2016, p. 615-632.

Research output: Contribution to journalReview article

Jayakumar, Thanasekaran ; Yang, Chih Hao ; Geraldine, Pitchairaj ; Yen, Ting Lin ; Sheu, Joen Rong. / The pharmacodynamics of antiplatelet compounds in thrombosis treatment. In: Expert Opinion on Drug Metabolism and Toxicology. 2016 ; Vol. 12, No. 6. pp. 615-632.
@article{0314127c3b4c43509ac43e3b677891ec,
title = "The pharmacodynamics of antiplatelet compounds in thrombosis treatment",
abstract = "ABSTRACT: Introduction: As it is importance to understand the involvement of platelets in the initiation and propagation of thrombosis, antiplatelet drugs have come to the forefront of atherothrombotic disease treatment. Dual antiplatelet therapy of aspirin plus clopidogrel has its benefits, but it also has its limitations with regard to its pharmacologic properties and adverse effects. For these reasons, within the last decade or so, the investigation of novel antiplatelet agents has prospered. Areas covered: In this review, we discuss the unique pharmacodynamic properties of several antiplatelet drugs with their possible potential molecular of mechanisms on inhibiting platelet aggregation. Expert opinion: Considering multiple synergetic pathways of platelet activation and their close interplay with coagulation, the current treatment strategies are not only based on platelet inhibition, they also rely on the attenuation of procoagulant activity, inhibition of thrombin generation, and enhancement of clot dissolution. Current guidelines recommend various antiplatelet agents in addition to aspirin for patients with acute coronary syndromes. The advantages of these agents, as repute mortality, may be associated with off-target effects of the drug. Hence, further studies are required to facilitate the physician’s choice of the most appropriate antiplatelet agents for each patient for thrombosis treatment.",
keywords = "Antiplatelets, antithrombotic, multi-targets, pharmacodynamics",
author = "Thanasekaran Jayakumar and Yang, {Chih Hao} and Pitchairaj Geraldine and Yen, {Ting Lin} and Sheu, {Joen Rong}",
year = "2016",
month = "6",
day = "2",
doi = "10.1080/17425255.2016.1176141",
language = "English",
volume = "12",
pages = "615--632",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - The pharmacodynamics of antiplatelet compounds in thrombosis treatment

AU - Jayakumar, Thanasekaran

AU - Yang, Chih Hao

AU - Geraldine, Pitchairaj

AU - Yen, Ting Lin

AU - Sheu, Joen Rong

PY - 2016/6/2

Y1 - 2016/6/2

N2 - ABSTRACT: Introduction: As it is importance to understand the involvement of platelets in the initiation and propagation of thrombosis, antiplatelet drugs have come to the forefront of atherothrombotic disease treatment. Dual antiplatelet therapy of aspirin plus clopidogrel has its benefits, but it also has its limitations with regard to its pharmacologic properties and adverse effects. For these reasons, within the last decade or so, the investigation of novel antiplatelet agents has prospered. Areas covered: In this review, we discuss the unique pharmacodynamic properties of several antiplatelet drugs with their possible potential molecular of mechanisms on inhibiting platelet aggregation. Expert opinion: Considering multiple synergetic pathways of platelet activation and their close interplay with coagulation, the current treatment strategies are not only based on platelet inhibition, they also rely on the attenuation of procoagulant activity, inhibition of thrombin generation, and enhancement of clot dissolution. Current guidelines recommend various antiplatelet agents in addition to aspirin for patients with acute coronary syndromes. The advantages of these agents, as repute mortality, may be associated with off-target effects of the drug. Hence, further studies are required to facilitate the physician’s choice of the most appropriate antiplatelet agents for each patient for thrombosis treatment.

AB - ABSTRACT: Introduction: As it is importance to understand the involvement of platelets in the initiation and propagation of thrombosis, antiplatelet drugs have come to the forefront of atherothrombotic disease treatment. Dual antiplatelet therapy of aspirin plus clopidogrel has its benefits, but it also has its limitations with regard to its pharmacologic properties and adverse effects. For these reasons, within the last decade or so, the investigation of novel antiplatelet agents has prospered. Areas covered: In this review, we discuss the unique pharmacodynamic properties of several antiplatelet drugs with their possible potential molecular of mechanisms on inhibiting platelet aggregation. Expert opinion: Considering multiple synergetic pathways of platelet activation and their close interplay with coagulation, the current treatment strategies are not only based on platelet inhibition, they also rely on the attenuation of procoagulant activity, inhibition of thrombin generation, and enhancement of clot dissolution. Current guidelines recommend various antiplatelet agents in addition to aspirin for patients with acute coronary syndromes. The advantages of these agents, as repute mortality, may be associated with off-target effects of the drug. Hence, further studies are required to facilitate the physician’s choice of the most appropriate antiplatelet agents for each patient for thrombosis treatment.

KW - Antiplatelets

KW - antithrombotic

KW - multi-targets

KW - pharmacodynamics

UR - http://www.scopus.com/inward/record.url?scp=84975123261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975123261&partnerID=8YFLogxK

U2 - 10.1080/17425255.2016.1176141

DO - 10.1080/17425255.2016.1176141

M3 - Review article

VL - 12

SP - 615

EP - 632

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 6

ER -